Segmentectomies: 5-Year Experience Of A Center

Authors

  • Catarina Nunes Figueiredo Thoracic Surgery Department – Hospital de Santa Marta, Centro Hospitalar Universitário Lisboa Central, Portugal https://orcid.org/0009-0006-5798-2545
  • Catarina Moita Thoracic Surgery Department – Hospital de Santa Marta, Centro Hospitalar Universitário Lisboa Central, Portugal
  • Zenito Cruz Thoracic Surgery Department – Hospital de Santa Marta, Centro Hospitalar Universitário Lisboa Central, Portugal
  • Ana Rita Costa Thoracic Surgery Department – Hospital de Santa Marta, Centro Hospitalar Universitário Lisboa Central, Portugal
  • João Santos Silva Thoracic Surgery Department – Hospital de Santa Marta, Centro Hospitalar Universitário Lisboa Central, Portugal
  • João Eurico Reis Thoracic Surgery Department – Hospital de Santa Marta, Centro Hospitalar Universitário Lisboa Central, Portugal
  • João Maciel Thoracic Surgery Department – Hospital de Santa Marta, Centro Hospitalar Universitário Lisboa Central, Portugal
  • Paulo Calvinho Thoracic Surgery Department – Hospital de Santa Marta, Centro Hospitalar Universitário Lisboa Central, Portugal

DOI:

https://doi.org/10.48729/pjctvs.419

Keywords:

Segmentectomy, Primary Lung Cancer, Surgery

Abstract

Introduction: Segmental anatomical resections have been a subject of debate in recent years. There is increasing evidence that these procedures may offer some advantages in the treatment of early-stage lung cancer, with overall survival (OS) and disease-free survival (DFS) similar to those seen in lobar anatomical resections.
Materials and Methods: We conducted a retrospective analysis of patients who underwent segmentectomy at Santa Marta Hospital (HSM) between January 2018 and September 2022. Patients undergoing trauma-related segmentectomy or as a secondary procedure were excluded.
Results: 37 segmentectomies were performed, of which 34 were included in this analysis. 29 (85.3%) were performed for malignancies, 5 (14.7%) for benign conditions. Of the malignancies, 24 (82.8%) were primary lung cancer (PLC): 18 (75%) adenocarcinomas (ADC), 2 (8.3%) squamous cell carcinomas (SCC), 4 (16.7%) typical carcinoids (TC); 5 (17.2%) were colorectal-origin metastases. Among the benign cases: 3 (60%) were aspergillomas. Mean age of PLC patients was 71 years (min=56;max=88), with 9 (37.5%) females and 15 (62.5%) males. In 11 (45.8%), FEV1 or DLCO was <60%. 18 (75%) were smokers. Lesions were mostly solid nodules (N=12;50%). Others included subsolid lesions (N=11;45%) and 1 (4.2%) cystic formation. At surgery, only 3 (12.5%) patients had a pre-operative histological diagnosis (ADC=2; SCC=1). 21 (87.5%) were stage IA, 2 (8.33%) patients were stage IB and 1 (8.33%) patient was stage IIA. Procedures were performed via VATS (N=17;70.8%), via thoracotomy (N=5;20.8%) and via RATS (N=2;8.3%). 23 (95.8%) were R0 resections.
Postoperatively: 19 (79.2%) were stage IA; 3 (12.5%) IB; ,1 (4.2%) IIB, and 1 (4.2%) IIIA. 3 (12.5%) had upstaging. 2 (8.3%) patients underwent adjuvant chemotherapy, 1 (4.2%) had completion lobectomy. 2 (8.3%) experienced recurrence. DFS was 100% at 3, 6, and 12 months, and at 3 and 5 years, was 88.9% and 66.7% respectively. OS was 100% at 3, 6, and 12 months and 95% at 3 and 5 years. Median follow up time was 29 months (IQR: 18 – 44).
Conclusion: This study reinforces the idea that segmental resections should be considered a viable option for patients with early-stage lung cancer. Although this analysis has some limitations, such as a limited number of preoperative histological diagnoses and postoperative upstaging, our results demonstrate promising OS and DFS, in accordance with recent literature.

Downloads

Download data is not yet available.

References

Iizasa T, Suzuki M, Yasufuku K, Iyoda A, Otsuji M, Yoshida S, et al. Preoperative pulmonary function as a prognostic factor for stage I non–small cell lung carcinoma. Ann Thorac Surg. 2004 Jun;77(6):1896–902.

Shennib H. Sublobar resection for lung cancer*1. European Journal of Cardio-Thoracic Surgery. 1999 Sep;16:S61–3.

Randomized Trial of Lobectomy Versus Limited Resection for T1 NO Non-Small Cell Lung Cancer. 1995.

Sagawa M, Oizumi H, Suzuki H, Uramoto H, Usuda K, Sakurada A, et al. A prospective 5-year follow-up study after limited resection for lung cancer with ground-glass opacity. European Journal of Cardio-thoracic Surgery. 2018 Apr 1;53(4):849–56.

de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. New England Journal of Medicine. 2020 Feb 6;382(6):503–13.

Kaneko M, Eguchi K, Ohmatsu H, Kakinuma R, Naruke T, Suemasu K. Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology. 1996;

Altorki NK, Yip R, Hanaoka T, Bauer T, Aye R, Kohman L, et al. Sublobar resection is equivalent to lobectomy for clinical stage 1A lung cancer in solid nodules. Journal of Thoracic and Cardiovascular Surgery. 2014 Feb;147(2):754–64.

Ghaly G, Rahouma M, Kamel MK, Nasar A, Harrison S, Nguyen AB, et al. Clinical Predictors of Nodal Metastases in Peripherally Clinical T1a N0 Non-Small Cell Lung Cancer. Annals of Thoracic Surgery. 2017 Oct 1;104(4):1153–8.

Bedetti B, Bertolaccini L, Rocco R, Schmidt J, Solli P, Scarci M. Segmentectomy versus lobectomy for stage I non-small cell lung cancer: A systematic review and meta-analysis. J Thorac Dis. 2017 Jun 1;9(6):1615–23.

Saji H, Okada M, Tsuboi M, Nakajima R, Suzuki K, Aokage K, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial [Internet]. Vol. 399, www.thelancet. com. 2022. Available from: www.thelancet.com

Altorki N, Wang X, Kozono D, Watt C, Landrenau R, Wigle D, et al. Lobar or Sublobar Resection for Peripheral Stage IA Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2023 Feb 9;388(6):489–98.

Ettinger D, Wood D, Chair V, Aisner D, Akerley W. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer NCCN Guidelines. 2022;

Cerfolio RJ, Ojha B, Bryant AS, Raghuveer V, Mountz JM, Bartolucci AA. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Annals of Thoracic Surgery. 2004 Sep;78(3):1017–23.

Moon Y, Kim KS, Lee KY, Sung SW, Kim YK, Park JK. Clinicopathologic Factors Associated With Occult Lymph Node Metastasis in Patients With Clinically Diagnosed N0 Lung Adenocarcinoma. Annals of Thoracic Surgery. 2016 May 1;101(5):1928–35.

Bousema JE, Heineman DJ, Dijkgraaf MGW, Annema JT, van den Broek FJC. Adherence to the mediastinal staging guideline and unforeseen N2 disease in patients with resectable non-small cell lung cancer: Nationwide results from the Dutch Lung Cancer Audit - Surgery. Lung Cancer. 2020 Apr 1;142:51–8.

Koike T, Nakamura A, Shimizu Y, Goto T, Sato S, Toyabe Sichi, et al. Characteristics and risk factors of recurrence in clinical stage I non-small cell lung cancer patients undergoing anatomic segmentectomy. Gen Thorac Cardiovasc Surg. 2020;

Chen X, Zhang Z, Xu N, Ma D, Li H. Review of Approaches to Developing Intersegmental Plane during Segmentectomy. Thorac Cardiovasc Surg. 2022 Jun 16;70(04):341–5.

Downloads

Published

12-10-2024

How to Cite

1.
Nunes Figueiredo C, Moita C, Cruz Z, Costa AR, Santos Silva J, Reis JE, Maciel J, Calvinho P. Segmentectomies: 5-Year Experience Of A Center. Rev Port Cir Cardiotorac Vasc [Internet]. 2024 Oct. 12 [cited 2024 Nov. 9];31(3):33-8. Available from: https://pjctvs.com/index.php/journal/article/view/419

Issue

Section

Original Articles

Categories

Most read articles by the same author(s)

1 2 > >>